Literature DB >> 18523992

Troponins and natriuretic peptides in the monitoring of anthracycline cardiotoxicity.

Ioannis Germanakis1, Nikol Anagnostatou, Maria Kalmanti.   

Abstract

Anthracycline-related cardiotoxicity has a substantial negative impact on long-term survivors of childhood cancer. The detection of cardiotoxicity is currently based on echocardiography or radionuclide angiography. However, as they depict only the final outcome of myocardial injury in terms of reduced heart contractility, heart specific biomarkers of myocardial destruction or dysfunction could be advantageous by allowing for an earlier detection of cardiotoxicity. In the present study, the usefulness of cardiac troponins and natriuretic peptides, the most commonly used biomarkers of myocardial destruction and ventricular dysfunction respectively, to detect and to predict the development of anthracycline cardiotoxicity has been reviewed. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18523992     DOI: 10.1002/pbc.21633

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  14 in total

1.  Evaluation of lecithinized human recombinant super oxide dismutase as cardioprotectant in anthracycline-treated breast cancer patients.

Authors:  Frederik J F Broeyer; Susanne Osanto; Jun Suzuki; Felix de Jongh; Henk van Slooten; Bea C Tanis; Tobias Bruning; Jeroen J Bax; Henk J Ritsema van Eck; Marieke L de Kam; Adam F Cohen; Yutaka Mituzhima; Jacobus Burggraaf
Journal:  Br J Clin Pharmacol       Date:  2014-11       Impact factor: 4.335

2.  Assessment of cardiotoxicity with cardiac biomarkers in cancer patients.

Authors:  D Cardinale; C M Cipolla
Journal:  Herz       Date:  2011-06       Impact factor: 1.443

Review 3.  Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 1.

Authors:  Hui-Ming Chang; Rohit Moudgil; Tiziano Scarabelli; Tochukwu M Okwuosa; Edward T H Yeh
Journal:  J Am Coll Cardiol       Date:  2017-11-14       Impact factor: 24.094

Review 4.  Biomarkers in cancer therapy related cardiac dysfunction (CTRCD).

Authors:  Rohit Moudgil; Parag A Parekh
Journal:  Heart Fail Rev       Date:  2018-03       Impact factor: 4.214

5.  Differential diurnal variations of anandamide and 2-arachidonoyl-glycerol levels in rat brain.

Authors:  M Valenti; D Viganò; M G Casico; T Rubino; L Steardo; D Parolaro; V Di Marzo
Journal:  Cell Mol Life Sci       Date:  2004-04       Impact factor: 9.261

Review 6.  Educational paper: decreasing the burden of cardiovascular disease in childhood cancer survivors: an update for the pediatrician.

Authors:  Rejane F Dillenburg; Paul Nathan; Luc Mertens
Journal:  Eur J Pediatr       Date:  2013-01-30       Impact factor: 3.183

7.  Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease.

Authors:  Brandon C Drafts; Katie M Twomley; Ralph D'Agostino; Julia Lawrence; Nancy Avis; Leslie R Ellis; Vinay Thohan; Jennifer Jordan; Susan A Melin; Frank M Torti; William C Little; Craig A Hamilton; W Gregory Hundley
Journal:  JACC Cardiovasc Imaging       Date:  2013-05-01

Review 8.  Cardiotoxicity and oncological treatments.

Authors:  Axel Schlitt; Karin Jordan; Dirk Vordermark; Jürgen Schwamborn; Thorsten Langer; Christoph Thomssen
Journal:  Dtsch Arztebl Int       Date:  2014-03-07       Impact factor: 5.594

Review 9.  Serum biomarkers for the detection of cardiac toxicity after chemotherapy and radiation therapy in breast cancer patients.

Authors:  Sibo Tian; Kim M Hirshfield; Salma K Jabbour; Deborah Toppmeyer; Bruce G Haffty; Atif J Khan; Sharad Goyal
Journal:  Front Oncol       Date:  2014-10-09       Impact factor: 6.244

10.  Strategies to prevent anthracycline-related congestive heart failure in survivors of childhood cancer.

Authors:  Saro H Armenian; Sarah K Gelehrter; Eric J Chow
Journal:  Cardiol Res Pract       Date:  2012-08-15       Impact factor: 1.866

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.